Over 100 Patients Buy Cannabis in Alabama’s First Sales Week

Alabama’s medical cannabis program produced its first week of retail data, and the figures describe a market still running through a single storefront. Callie’s Apothecary in Montgomery — the only licensed dispensary open in the state — recorded 102 patients across 111 transactions and roughly $14,600 in pre-tax sales in the week after it opened on June 4, 2026, the Alabama Medical Cannabis Commission reported at its meeting.

For a state that waited five years to move a single gram of regulated product, the numbers are modest but clean: an average ticket of $131.56, generated by patients buying from a tightly restricted menu. The early dataset is the first real read on how Alabama’s unusually narrow program behaves at the register. The launch caps a program lawmakers created in 2021 that then spent years tangled in licensing disputes; the three dispensary licenses now in hand were not approved until December 2025, after repeated fights over how the commission scored applications.

Inside the first-week numbers

The math points to patients stocking up rather than sampling. With individual products priced between $42 and $52, an average transaction north of $130 means most buyers left with two or three items — consistent with a program built around 60-day supply windows rather than casual repeat visits.

Supply, not demand, sets the early pace. Callie’s owner, Vince Schilleci, said the store capped purchase sizes during the opening days to spread thin inventory across an incoming wave of patients. “We’ve had to—I hate to use this term ration—but we’ve limited how much patients could purchase,” he said, adding that the store lifted the limits after a second product shipment arrived and a third was due, freeing patients to buy their full 60-day allotment.

Alabama’s menu is among the most restrictive in the country. The products reaching shelves so far are all non-smokable — tablets, tinctures, transdermal patches, oils, and peach-flavored gelatinous cubes — and while state rules permit a somewhat wider set of processed formats, raw flower, vapes, and conventional edibles remain banned outright. That constraint shapes the unit economics. Without flower, the highest-volume category in most state markets, Alabama operators are selling a smaller catalog of processed goods at fixed price points, and average tickets reflect deliberate, supply-limited purchases rather than impulse volume.

A thin pipeline of patients and physicians

The addressable market is still forming. As of the commission’s update, 481 people had applied for a medical cannabis card, and 446 had been issued one — a registered patient base barely larger than a single week’s foot traffic at one store.

The bottleneck sits upstream, with the physicians who gate access. Alabama requires a registered doctor’s recommendation, not a prescription, and the supply of willing recommenders is thin. The Alabama Board of Medical Examiners has certified 52 physicians, but only 39 have completed registration with the commission, and just 21 have actually recommended cannabis to a patient. Those doctors can recommend it for about 15 qualifying conditions, including cancer, chronic pain, PTSD, and Parkinson’s disease. Until the recommender count grows, the registry — and the sales it feeds — stays small.

Supply and geography still constrain the market

One open store cannot serve a state. The commission cleared three companies for dispensary licenses — CCS of Alabama, which operates Callie’s, along with GP6 Wellness and RJK Holdings — each authorized for up to three locations, for nine sites statewide. Only the Montgomery store is trading; the commission expects the others to open over the summer. A fourth license remains stayed in litigation and is expected to go to Yellowhammer Medical Dispensaries once the appeal clears. Separately, the commission is still working through hearings on integrated-facility licenses — vertically integrated operators that could each run up to five stores, potentially adding as many as 25 more retail sites once those awards survive the inevitable court challenges.

The distribution layer behind those stores is just as lean. Alabama has licensed a single testing laboratory, and at the same meeting, the commission voted to reopen applications for additional lab licenses — a tacit acknowledgment that one testing site is a chokepoint for a supply chain trying to keep processed inventory flowing to a growing number of dispensaries. Commission staff said they are working with processors to widen the product range so the lone open store can carry a deeper inventory.

That ramp mirrors early-market dynamics playing out elsewhere. Iowa is moving to double its medical dispensary footprint to widen access, while mature markets like Michigan now contend with falling prices and oversupply — the opposite problem from Alabama’s supply-constrained launch.

For now, the operators living the launch are focused on the patients walking in. Schilleci described watching that first week from behind the counter: “Our store manager saw a patient walking out, and as silly as it sounds, they jumped and clicked their heels. Yeah, they were that happy about having that medicine.” The harder test is whether the supply chain and the physician pipeline can scale fast enough to turn one happy storefront into a functioning statewide market.